Comment on: ‘One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration’
Crossref DOI link: https://doi.org/10.1038/eye.2017.211
Published Online: 2017-10-13
Published Print: 2018-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Nestel, A R
Text and Data Mining valid from 2017-10-13
Article History
First Online: 13 October 2017
Competing interests
: ARN has received consultancy fees and travel grants from Novartis and Bayer.